Citadel Advisors
RXRX icon

Citadel Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Citadel Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Sell
798,900
-1,166,700
-59% -$4.51M ﹤0.01% 5663
2025
Q4 		$8.04M Buy
1,965,600
+875,400
+80% +$4.34M ﹤0.01% 3548
2025
Q3 		$5.32M Buy
1,090,200
+391,253
+56% +$2.05M ﹤0.01% 4248
2025
Q2 		$3.54M Sell
698,947
-660,938
-49% -$3.25M ﹤0.01% 4696
2025
Q1 		$7.19M Buy
1,359,885
+51,041
+4% +$372K ﹤0.01% 3327
2024
Q4 		$8.85M Buy
1,308,844
+752,144
+135% +$5.06M ﹤0.01% 3135
2024
Q3 		$3.67M Buy
556,700
+6,600
+1% +$47.3K ﹤0.01% 4449
2024
Q2 		$4.13M Buy
550,100
+312,800
+132% +$2.73M ﹤0.01% 4052
2024
Q1 		$2.37M Buy
237,300
+152,800
+181% +$1.7M ﹤0.01% 5196
2023
Q4 		$833K Buy
84,500
+1,000
+1% +$7.13K ﹤0.01% 7043
2023
Q3 		$639K Buy
83,500
+75,600
+957% +$754K ﹤0.01% 7537
2023
Q2 		$59K Sell
7,900
-15,100
-66% -$106K ﹤0.01% 11609
2023
Q1 		$153K Buy
23,000
+21,700
+1,669% +$172K ﹤0.01% 10605
2022
Q4 		$10K Sell
1,300
-10,200
-89% -$100K ﹤0.01% 13647
2022
Q3 		$122K Sell
11,500
-3,700
-24% -$37.5K ﹤0.01% 10924
2022
Q2 		$124K Buy
+15,200
New +$102K ﹤0.01% 11179

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's RXRX Position: Q1 2026 in Review

Citadel Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 85% in Q1 2026, selling an estimated $13.9M and leaving 624,659 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #6142.

Citadel Advisors first reported a position in RXRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $18.5M in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Citadel Advisors held 624,659 shares of Recursion Pharmaceuticals worth $1.92M as of Q1 2026.
  • Citadel Advisors sold 3,605,340 Recursion Pharmaceuticals shares in Q1 2026, an estimated $13.9M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6142 holding.
  • Citadel Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Recursion Pharmaceuticals position peaked at $18.5M in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.